or Try an Advanced Search...

    ETF Components for JDOC - JPMorgan Healthcare Leaders ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    LLY B -0.95 9.41
    UNH D -1.68 7.78
    NVO C -2.87 6.10
    REGN B -1.97 4.70
    ABBV C -1.28 4.57
    DHR D -0.17 3.45
    SYK C -0.68 2.87
    JNJ F -0.23 2.86
    CI D -0.15 2.78

    Represented by ETF Holdings

    Keywords: S&P 500 Pharmaceutical Products Atopic Dermatitis Biopharmaceutical Bone Cardiovascular Disease Cholesterol Depressive Disorder Diabetes Disability Dow Jones Component Growth Hormone Immunology Infection Infectious Diseases Inflammation Insulin Medicaid Medicine Mental Health
    Industries: Drug Manufacturers - Major Biotechnology Health Care Plans Diagnostics & Research Medical Devices

    Recent News for JPMorgan Healthcare Leaders ETF & its Holdings

    Date Stock Title
    Jul 3 ABBV AbbVie Q2 IPR&D expenses to lower EPS by $0.52
    Jul 3 LLY Lilly's new Alzheimer's drug could generate $7.1B in sales: analyst
    Jul 3 NVO S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
    Jul 3 LLY S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
    Jul 3 NVO Using Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk's Ozempic And Wegovy, Study Finds
    Jul 3 LLY Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
    Jul 3 NVO Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
    Jul 3 NVO Weight-loss drugs linked to rare vision loss: Harvard study
    Jul 3 LLY Weight-loss drugs linked to rare vision loss: Harvard study
    Jul 3 NVO Update: Ozempic, Wegovy Linked to Risk of Blinding Eye Condition, Study Shows
    Jul 3 NVO Novo Nordisk’s Ozempic, Wegovy linked to eye disorder in small study
    Jul 3 LLY ADP jobs data, Constellation Brands, summer gas prices: Morning Brief
    Jul 3 LLY Ozempic Linked to Rare Cases of Vision Loss in Harvard Study
    Jul 3 NVO Ozempic Linked to Rare Cases of Vision Loss in Harvard Study
    Jul 3 NVO Ozempic, Wegovy Linked to Risk of Blinding Eye Condition, Study Shows
    Jul 3 UNH The Dow Is Dipping. Blame UnitedHealth Stock.
    Jul 3 LLY FDA Approves Eli Lilly's Alzheimer's Drug Kisunla
    Jul 3 UNH Unpacking the Latest Options Trading Trends in UnitedHealth Group
    Jul 3 JNJ Johnson & Johnson: A Lot Of Moving Parts, But Perhaps Finally Lurching In The Right Direction
    Jul 3 JNJ Johnson & Johnson: Put Selling Can Yield A Potential 9.8% Return
    The fund will invest primarily in equity securities issued by pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology and life sciences companies which the adviser believes are leaders and where the magnitude and/or duration of future growth for these companies is underappreciated by the market. Under normal circumstances, the fund invests at least 80% of its assets in the equity securities of healthcare companies.
    Biotechnology Venture Capital Medical Technology Healthcare Service Healthcare Technology
    Back to the Main JDOC Page...